Breast Cancer

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Ian E. Krop, MD, PhD, discusses the pivotal data from the DESTINY-Breast01 trial, the need for longer-term follow-up with trastuzumab deruxtecan, and the proper management of interstitial lung disease.

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival for these patients, and a number of agents on the horizon.

Hatem Soliman, MD, discusses new therapeutic approaches for patients with metastatic triple-negative breast cancer.

The novel antibody-drug conjugate sacituzumab govitecan-hziy demonstrated significant improvement in survival in patients with triple-negative breast cancer without brain metastases who previously received at least 2 prior therapies for metastatic disease.

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.